Lipid Metabolism Practice Questions

Q: Which metabolic disorder is characterized by the accumulation of sphingomyelin in lysosomes?

Niemann-Pick disease. ***Niemann-Pick disease*** - This lysosomal storage disorder is specifically characterized by the accumulation of **sphingomyelin** due to a deficiency in the enzyme **sphingomyelinase**. - Clinical manifestations include **hepatosplenomegaly**, neurodegeneration, and a **cherry-red spot** on the retina in some types. *Tay-Sachs disease* - This disorder involves the accumulation of **GM2 gangliosides** in lysosomes due to a deficiency of **hexosaminidase A**. - It primarily affects the central nervous system, leading to **progressive neurodegeneration** and a cherry-red spot in the macula. *Gaucher disease* - Characterized by the buildup of **glucocerebroside** in lysosomes, caused by a deficiency in the enzyme **glucocerebrosidase**. - Key features include **hepatosplenomegaly**, bone pain, and neurologic manifestations in severe forms. *Fabry disease* - This X-linked disorder results from a deficiency of **alpha-galactosidase A**, leading to the accumulation of **globotriaosylceramide (Gb3)**. - Clinical signs include **acroparesthesias**, angiokeratomas, renal failure, and cardiac involvement.

Q: What is the biochemical effect of a deficiency in the enzyme hexosaminidase A on ganglioside metabolism?

Accumulation of GM2 ganglioside due to impaired degradation. ***Accumulation of GM2 ganglioside due to impaired degradation*** - Hexosaminidase A is responsible for the catabolism of **GM2 ganglioside** by removing the terminal N-acetylgalactosamine. - Deficiency leads to the **lysosomal accumulation** of GM2 ganglioside, primarily in neural tissues, causing neurodegeneration. *No change in sphingomyelin synthesis* - Sphingomyelin synthesis and degradation are primarily managed by **sphingomyelinase**, an enzyme distinct from hexosaminidase A. - A deficiency in hexosaminidase A specifically affects **ganglioside metabolism**, not sphingomyelin. *No significant change in ceramide production* - Ceramide is a precursor to many sphingolipids, including gangliosides, and its production is upstream of ganglioside catabolism. - Hexosaminidase A deficiency impacts the **degradation of specific gangliosides**, not the synthesis of ceramide. *Impaired glycolipid degradation without specific accumulation* - Hexosaminidase A deficiency leads to a **very specific accumulation** (GM2 ganglioside), not a general, non-specific impairment of glycolipid degradation. - The disease associated with this deficiency (Tay-Sachs disease) is characterized by this **particular lipid storage**.

Q: Which of the following metabolic changes is characteristic of diabetic ketoacidosis?

Hyperketonemia. ***Hyperketonemia*** - Diabetic ketoacidosis (DKA) is characterized by **uncontrolled ketone body production** due to severe insulin deficiency and increased counter-regulatory hormones. - This leads to a significant increase in blood **ketone levels**, such as beta-hydroxybutyrate and acetoacetate. *Hypoglycemia* - DKA is fundamentally a state of **absolute or relative insulin deficiency**, leading to **hyperglycemia**, not hypoglycemia. - The lack of insulin prevents glucose uptake by cells, causing high blood sugar. *Hypoketonemia* - **Hypoketonemia** means abnormally low levels of ketones, which is the opposite of what occurs in DKA. - DKA is defined by the **overproduction and accumulation of ketones**, leading to metabolic acidosis. *Hyperinsulinemia* - DKA is caused by an **absolute or relative deficiency of insulin**, leading to high blood glucose and ketone production. - **Hyperinsulinemia** would inhibit lipolysis and ketogenesis, thus preventing DKA.

Q: In lipid metabolism, what is the primary role of lipoprotein lipase?

To hydrolyze triglycerides in chylomicrons and VLDLs. ***To hydrolyze triglycerides in chylomicrons and VLDLs*** - **Lipoprotein lipase (LPL)** is an enzyme located on the endothelial surface of capillaries, where it acts to break down **triglycerides** carried in **chylomicrons** and **very-low-density lipoproteins (VLDLs)**. - This hydrolysis releases **fatty acids** and **glycerol**, which can then be taken up by surrounding tissues (e.g., adipose tissue, muscle) for energy or storage. *To synthesize triglycerides in adipose tissue* - The synthesis of **triglycerides** in adipose tissue is primarily carried out by enzymes within the adipocytes, such as **acyl-CoA:diacylglycerol acyltransferase (DGAT)**, using fatty acids and glycerol-3-phosphate. - LPL’s role is on the *outside* of the cell, making fatty acids available for uptake, not *synthesizing* within the cell. *To convert cholesterol into bile acids* - The conversion of **cholesterol** into **bile acids** occurs in the **liver** and is catalyzed by a series of enzymes, with **cholesterol 7α-hydroxylase** being the rate-limiting step. - This process is distinct from the function of LPL, which is involved in triglyceride metabolism. *To package triglycerides into VLDLs in the liver* - The packaging of **triglycerides** into **VLDLs** takes place within **hepatocytes** (liver cells) and involves the action of **microsomal triglyceride transfer protein (MTP)** and other enzymes. - LPL does not participate in this intracellular process but rather acts on VLDLs once they are secreted into the bloodstream.

Q: What is the primary metabolic disorder that characteristically causes severe hypertriglyceridemia?

Familial chylomicronemia syndrome. ***Familial chylomicronemia syndrome*** - This syndrome is characterized by a severe deficiency in **lipoprotein lipase (LPL)** activity or its cofactors, leading to the accumulation of **chylomicrons** in the bloodstream [1]. - The inability to clear chylomicrons results in extremely high **triglyceride levels**, often exceeding 1000 mg/dL, which can cause pancreatitis and eruptive xanthomas [1]. *Familial hypercholesterolemia* - This genetic disorder primarily affects the metabolism of **low-density lipoprotein (LDL) cholesterol**, leading to very high **LDL levels** [2]. - While it can be associated with some increase in triglycerides, **hypertriglyceridemia** is not its primary or characteristic feature [1]. *Type 2 diabetes mellitus* - Poorly controlled **Type 2 diabetes** can cause **secondary hypertriglyceridemia** due to increased very-low-density lipoprotein (VLDL) production and impaired triglyceride clearance [3]. - However, it's a secondary cause and often does not reach the extremely high levels seen in primary chylomicronemia syndromes unless compounded by other factors. *Hypothyroidism* - **Hypothyroidism** can lead to **dyslipidemia**, primarily characterized by elevated **LDL cholesterol** and moderately elevated **triglycerides** due to decreased LPL activity and slower chylomicron clearance. - While it can cause hypertriglyceridemia, the severity typically does not approximate the extreme levels seen in familial chylomicronemia syndrome.

Q: A patient with hyperlipidemia is found to have elevated levels of chylomicrons. Which apolipoprotein deficiency is most likely?

ApoCII. ***Correct Answer: ApoCII*** - **ApoCII** is a crucial activator of **lipoprotein lipase (LPL)**, an enzyme responsible for hydrolyzing triglycerides within chylomicrons and VLDL. - A deficiency in **ApoCII** leads to impaired LPL activity, causing **chylomicrons** to accumulate in the bloodstream after a meal, resulting in severe hypertriglyceridemia (Type I hyperlipoproteinemia or familial chylomicronemia syndrome). *Incorrect: ApoB100* - **ApoB100** is primarily found on **LDL** and **VLDL** particles, where it serves as the ligand for the **LDL receptor**. - Deficiency in **ApoB100** (or defective **ApoB100**) typically leads to **hypobetalipoproteinemia** or **familial hypocholesterolemia**, not elevated chylomicrons. *Incorrect: ApoE* - **ApoE** is essential for the receptor-mediated uptake of **chylomicron remnants** and **VLDL remnants** by the liver. - A deficiency or defective **ApoE** results in **Type III hyperlipoproteinemia** (familial dysbetalipoproteinemia), characterized by the accumulation of remnants, not intact chylomicrons. *Incorrect: ApoA1* - **ApoA1** is the primary apolipoprotein of **HDL** and plays a critical role in **reverse cholesterol transport** by activating lecithin-cholesterol acyltransferase (LCAT). - Deficiency in **ApoA1** leads to very low **HDL** levels and impaired cholesterol efflux, but it does not directly cause an accumulation of chylomicrons.

Q: A 54-year-old male presents with exercise intolerance, weakness, and myalgia following fasting. Laboratory results show elevated creatine kinase and elevated acylcarnitines. What is the likely enzyme deficiency?

Carnitine palmitoyltransferase II. ***Carnitine palmitoyltransferase II*** * **Carnitine palmitoyltransferase II (CPT II)** deficiency is a disorder of **fatty acid oxidation** and is typically triggered by **fasting** or intense exercise due to increased reliance on fat as an energy source. * The presentation of **exercise intolerance**, **weakness**, **myalgia**, **elevated creatine kinase (CK)**, and **elevated acylcarnitines** perfectly matches the clinical picture of CPT II deficiency. *Glucose-6-phosphate dehydrogenase (G6PD)* * **G6PD deficiency** primarily affects **red blood cells**, leading to **hemolytic anemia** in response to oxidative stress (e.g., fava beans, certain medications). * It does **not typically cause myalgia**, exercise intolerance, or elevated CK and acylcarnitines as its primary symptoms. *Pyruvate dehydrogenase (PDH)* * **Pyruvate dehydrogenase (PDH)** deficiency affects the conversion of pyruvate to acetyl-CoA, impairing **carbohydrate metabolism** and leading to **lactic acidosis**. * While it can cause exercise intolerance and neurological symptoms, the constellation of elevated CK and acylcarnitines, especially in response to fasting, points away from PDH deficiency as the primary cause. *Phosphofructokinase (PFK)* * **Phosphofructokinase (PFK)** deficiency (Tarui disease) is a disorder of **glycogenolysis** that primarily impairs the breakdown of glycogen for energy. * This condition typically results in **exercise intolerance**, **hemolytic anemia**, and **rhabdomyolysis**, but it would not typically cause elevated acylcarnitines, which are characteristic of fatty acid oxidation defects.

Q: In familial hypercholesterolemia, what is the effect of defective LDL receptors on lipid metabolism and cardiovascular risk?

Increased plasma LDL levels; atherosclerosis. ***Increased plasma LDL levels; atherosclerosis*** - Defective **LDL receptors** prevent the efficient uptake of **LDL cholesterol** from the bloodstream by cells, leading to its accumulation in the plasma. - Chronically elevated **plasma LDL levels** promote the formation of **atherosclerotic plaques** in arteries, significantly increasing cardiovascular risk. *Increased HDL levels; no change in cardiovascular health* - **Familial hypercholesterolemia** is primarily characterized by elevated **LDL** due to receptor defects, not increased **HDL**. **High-density lipoprotein (HDL)** levels are generally not directly affected by LDL receptor function. - While high HDL is generally considered protective, the severe elevation in LDL overrides any potential protective effect of unchanged or slightly altered HDL, leading to a substantial increase in cardiovascular risk. *Decreased VLDL production; increased triglycerides* - **VLDL (very-low-density lipoprotein)** production is mainly regulated by the liver's synthesis of triglycerides, which is not directly impaired by defective **LDL receptors**. - While hypertriglyceridemia can occur in some dyslipidemias, it is not the primary feature or direct consequence of defective LDL receptors in **familial hypercholesterolemia**, which is fundamentally about LDL clearance. *Decreased plasma LDL levels; increased atherosclerosis* - Defective **LDL receptors** lead to *increased*, not decreased, plasma **LDL levels**, as the receptors are responsible for clearing LDL from circulation. - Increased plasma LDL levels are the direct cause of increased **atherosclerosis** in familial hypercholesterolemia, making this option contradictory.

Q: The synthesis of which compound is directly inhibited by statins in cholesterol-lowering therapy?

Mevalonate. ***Mevalonate*** - Statins **inhibit HMG-CoA reductase**, the rate-limiting enzyme in the **mevalonate pathway**. - This inhibition directly blocks the conversion of **HMG-CoA to mevalonate**, which is a crucial precursor for cholesterol synthesis. *Cholesterol* - While statins ultimately reduce **cholesterol synthesis**, they do so indirectly by inhibiting an upstream precursor in the pathway. - The direct product whose synthesis is blocked by statin action on HMG-CoA reductase is mevalonate, not cholesterol itself. *Fatty acids* - **Fatty acid synthesis** primarily involves enzymes such as **acetyl-CoA carboxylase** and **fatty acid synthase**, which are not directly targeted by statins. - Statins specifically affect the **mevalonate pathway**, which is distinct from fatty acid synthesis. *Amino acids* - **Amino acid synthesis** pathways are entirely different from the cholesterol synthesis pathway and involve various specific enzymes and substrates. - Statins have no direct inhibitory effect on the synthesis of **amino acids**.

Q: Which enzyme is defective in the lysosomal storage disorder known as Gaucher's disease?

Glucocerebrosidase. ***Glucocerebrosidase*** - **Gaucher's disease** is caused by a deficiency in the enzyme **glucocerebrosidase**, leading to the accumulation of glucocerebroside in lysosomes. - This accumulation primarily affects **macrophages**, resulting in hepatosplenomegaly, bone pain, and neurological symptoms in certain types. *Hexosaminidase A* - A deficiency in **hexosaminidase A** is characteristic of **Tay-Sachs disease**, another lysosomal storage disorder. - This deficiency leads to the buildup of **GM2 gangliosides**, primarily affecting the central nervous system and causing neurodegeneration. *Sphingomyelinase* - A defect in **sphingomyelinase** is the underlying cause of **Niemann-Pick disease**, specifically types A and B. - This enzyme deficiency results in the accumulation of **sphingomyelin** in various organs, leading to hepatosplenomegaly and neurodegeneration. *Galactosidase* - While several types of galactosidases exist, a deficiency in **alpha-galactosidase A** is responsible for **Fabry disease**. - This deficiency causes the accumulation of **globotriaosylceramide (Gb3)**, primarily affecting the kidneys, heart, and nervous system, and not associated with Gaucher's.

Question 1

Which metabolic disorder is characterized by the accumulation of sphingomyelin in lysosomes?

Accepted Answer

Niemann-Pick disease

Answer

Tay-Sachs disease

Answer

Gaucher disease

Answer

Fabry disease

Question 2

What is the biochemical effect of a deficiency in the enzyme hexosaminidase A on ganglioside metabolism?

Accepted Answer

Accumulation of GM2 ganglioside due to impaired degradation

Answer

No change in sphingomyelin synthesis

Answer

No significant change in ceramide production

Answer

Impaired glycolipid degradation without specific accumulation

Question 3

Which of the following metabolic changes is characteristic of diabetic ketoacidosis?

Accepted Answer

Hyperketonemia

Answer

Hypoglycemia

Answer

Hypoketonemia

Answer

Hyperinsulinemia

Question 4

In lipid metabolism, what is the primary role of lipoprotein lipase?

Accepted Answer

To hydrolyze triglycerides in chylomicrons and VLDLs

Answer

To synthesize triglycerides in adipose tissue

Answer

To convert cholesterol into bile acids

Answer

To package triglycerides into VLDLs in the liver

Question 5

What is the primary metabolic disorder that characteristically causes severe hypertriglyceridemia?

Accepted Answer

Familial chylomicronemia syndrome

Answer

Familial hypercholesterolemia

Answer

Type 2 diabetes mellitus

Answer

Hypothyroidism

Question 6

A patient with hyperlipidemia is found to have elevated levels of chylomicrons. Which apolipoprotein deficiency is most likely?

Accepted Answer

ApoCII

Answer

ApoB100

Answer

ApoE

Answer

ApoA1

Question 7

A 54-year-old male presents with exercise intolerance, weakness, and myalgia following fasting. Laboratory results show elevated creatine kinase and elevated acylcarnitines. What is the likely enzyme deficiency?

Accepted Answer

Carnitine palmitoyltransferase II

Answer

Glucose-6-phosphate dehydrogenase

Answer

Pyruvate dehydrogenase

Answer

Phosphofructokinase

Question 8

In familial hypercholesterolemia, what is the effect of defective LDL receptors on lipid metabolism and cardiovascular risk?

Accepted Answer

Increased plasma LDL levels; atherosclerosis

Answer

Increased HDL levels; no change in cardiovascular health

Answer

Decreased VLDL production; increased triglycerides

Answer

Decreased plasma LDL levels; increased atherosclerosis

Question 9

The synthesis of which compound is directly inhibited by statins in cholesterol-lowering therapy?

Accepted Answer

Mevalonate

Answer

Cholesterol

Answer

Fatty acids

Answer

Amino acids

Question 10

Which enzyme is defective in the lysosomal storage disorder known as Gaucher's disease?

Accepted Answer

Glucocerebrosidase

Answer

Hexosaminidase A

Answer

Sphingomyelinase

Answer

Galactosidase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?